Reviewer's report

**Title:** Sorafenib modulates the radiosensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner

**Version:** 1  **Date:** 8 July 2012

**Reviewer:** Adam P Dicker

**Reviewer's report:**

Nicely done manuscript  
The Radiation Therapy Oncology Group (www.rtog.org) will be evaluating the combination of sorafenib and stereotactic body radiotherapy in a randomized phase II trial

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

No conflicts or disclosures